KR102243243B1 - 신규한 cho 통합 부위 및 이의 용도 - Google Patents

신규한 cho 통합 부위 및 이의 용도 Download PDF

Info

Publication number
KR102243243B1
KR102243243B1 KR1020177012465A KR20177012465A KR102243243B1 KR 102243243 B1 KR102243243 B1 KR 102243243B1 KR 1020177012465 A KR1020177012465 A KR 1020177012465A KR 20177012465 A KR20177012465 A KR 20177012465A KR 102243243 B1 KR102243243 B1 KR 102243243B1
Authority
KR
South Korea
Prior art keywords
site
exogenous
goi
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012465A
Other languages
English (en)
Korean (ko)
Other versions
KR20170096999A (ko
Inventor
잉 셴
다리야 부라코프
강 첸
제임스 피. 팬들
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102243243(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20170096999A publication Critical patent/KR20170096999A/ko
Application granted granted Critical
Publication of KR102243243B1 publication Critical patent/KR102243243B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020177012465A 2014-10-23 2015-10-21 신규한 cho 통합 부위 및 이의 용도 Active KR102243243B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
US62/067,774 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (2)

Publication Number Publication Date
KR20170096999A KR20170096999A (ko) 2017-08-25
KR102243243B1 true KR102243243B1 (ko) 2021-04-22

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012465A Active KR102243243B1 (ko) 2014-10-23 2015-10-21 신규한 cho 통합 부위 및 이의 용도

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434A (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI747808B (enExample)
WO (1) WO2016064999A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005306A (es) 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
MX2018012868A (es) 2016-04-20 2019-03-11 Regeneron Pharma Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
SG10202010156XA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3559236A4 (en) * 2016-12-20 2020-11-04 Development Center for Biotechnology TARGETED INTEGRATION SITES IN THE CHINESE HAMSTER OVARIAN CELL GENOME
US20210309988A1 (en) * 2017-02-07 2021-10-07 Sigma-Aldrich Co. Llc Stable targeted integration
US11781116B2 (en) * 2017-02-17 2023-10-10 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
WO2018175153A1 (en) * 2017-03-19 2018-09-27 Applied Stemcell, Inc. Novel integration sites and uses thereof
US11560549B2 (en) 2017-08-11 2023-01-24 Boehringer Ingelheim International Gmbh Integration sites in CHO cells
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
WO2019126562A1 (en) * 2017-12-22 2019-06-27 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN113631711B (zh) * 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
EP3950938A4 (en) * 2019-04-02 2023-01-18 Chugai Seiyaku Kabushiki Kaisha PROCEDURE FOR INTRODUCING A TARGET-SPECIFIC ALIEN
AU2020308002A1 (en) 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
BR112022024644A2 (pt) * 2020-06-02 2023-02-23 Catalent Pharma Solutions Llc Linhagens celulares com múltiplas ancoragens para inserção de gene
EP4172346A1 (en) * 2020-06-24 2023-05-03 Genentech, Inc. Targeted integration of nucleic acids
KR20230085929A (ko) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Va rna 전사를 위한 핵산 구조체
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
US20230304062A1 (en) 2021-10-18 2023-09-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
US12234472B2 (en) 2021-10-18 2025-02-25 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202334402A (zh) 2021-10-18 2023-09-01 美商再生元醫藥公司 包含整合ｃａｓ９基因以產生穩定整合位點的哺乳動物細胞，以及包含穩定整合位點及其他位點的哺乳動物細胞
AU2023213996A1 (en) * 2022-01-28 2024-06-27 The Trustees Of Columbia University In The City Of New York Genetic modifications for xenotransplantation
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ATE539161T1 (de) 1998-07-21 2012-01-15 Millipore Corp Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
WO2002081632A2 (en) 2001-04-04 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
AU2009322964B2 (en) * 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
KR101999410B1 (ko) 2011-04-05 2019-07-11 더 스크립스 리서치 인스티튜트 염색체 랜딩 패드 및 관련된 용도
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
ES2713529T3 (es) * 2011-06-01 2019-05-22 Prec Biosciences Inc Procedimientos y productos para la producción de líneas celulares de mamífero modificadas con transgenes amplificados
US8895264B2 (en) * 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
MX2017005306A (es) 2014-10-23 2018-01-09 Regeneron Pharma Novedosos sitios de integracion en celulas cho y usos de estos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cytotechnology.,51(3):171-182(2006.11.15.)
Nat Biotechnol.,29(8):735-741(2011.7.31.)
Nat Biotechnol.,31(8):759-765(2013.6.21.)

Also Published As

Publication number Publication date
KR20170096999A (ko) 2017-08-25
US20160115502A1 (en) 2016-04-28
AR102420A1 (es) 2017-03-01
EA037255B1 (ru) 2021-02-26
US20180030480A1 (en) 2018-02-01
MX2017005306A (es) 2018-01-09
US9816110B2 (en) 2017-11-14
IL251674B (en) 2020-10-29
SG11201703149RA (en) 2018-02-27
US12565667B2 (en) 2026-03-03
EP3209785A1 (en) 2017-08-30
AU2015335921A1 (en) 2017-05-04
IL251674A0 (en) 2017-06-29
US20210171984A1 (en) 2021-06-10
MY184103A (en) 2021-03-18
US20200002732A1 (en) 2020-01-02
TWI780847B (zh) 2022-10-11
JP6668340B2 (ja) 2020-03-18
TW201629229A (zh) 2016-08-16
US20240018553A1 (en) 2024-01-18
TWI747808B (zh) 2021-12-01
CN107109434A (zh) 2017-08-29
BR112017008022A2 (pt) 2018-02-20
CA2965495A1 (en) 2016-04-28
US11788102B2 (en) 2023-10-17
TW202144576A (zh) 2021-12-01
WO2016064999A1 (en) 2016-04-28
CA2965495C (en) 2022-05-24
EA201790698A1 (ru) 2018-01-31
EP3209785B1 (en) 2019-07-31
JP2017535258A (ja) 2017-11-30
AU2015335921B2 (en) 2020-06-25
US11268109B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
US12565667B2 (en) CHO integration sites and uses thereof
US12214054B2 (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
CN109071633B (zh) 基于使用表达增强性基因座来制备抗体的组合物和方法
CN106893739A (zh) 用于靶向基因操作的新方法和系统
JP2021512617A (ja) ＣｏｒｙｎｅｂａｃｔｅｒｉｕｍにおいてＣＲＩＳＰＲを使用するゲノム編集
JP2019503653A (ja) トランスポゾン系、それを含むキット及びそれらの使用
EP1815001B1 (en) Gene trap cassettes for random and targeted conditional gene inactivation
Li et al. Versatile and efficient mammalian genome editing with Type IC CRISPR System of Desulfovibrio vulgaris
JP7109009B2 (ja) 遺伝子ノックアウト方法
EP4612306A2 (en) A screening method
TWI704224B (zh) 編輯核酸序列之組成物及方法
EP4506455A1 (en) Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same
HK1235432B (en) Novel cho integration sites and uses thereof
HK1235432A1 (en) Novel cho integration sites and uses thereof
JP2007124915A (ja) リコンビニアリングコンストラクト、及びジーンターゲティングコンストラクト作製用ベクター
CN117597439A (zh) Ciita靶向锌指核酸酶
HK40096853A (zh) Regnase-1和/或tgfbrii被破坏的基因工程化t细胞具有改善的功能性和持久性
da Fonseca Lopes Easy Embryonicstem Cell: A new Tool to Manipulate Gene Expression in Embryoid Bodies
Lopes Easy embryonicStem cell: a new tool to manipulate gene expression in embryoid bodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6